¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æרҵ£º 5Zuk`%O  
aNUM F  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ js;k,`  
W4q |55  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) d]vom@iI  
3w}ul~>j  
1. ICAM-1 VQ;'SY:`  
/HVxZ2bar  
2. interleukin 12(IL-12) I#/"6%e  
c)Ne/E{!0  
3. tumor infiltrating lymphocyte [&pMU)   
Ys]cJ]  
4. TCR/CD3 complex nCDG PzJ  
C6A!JegU  
5. hematopoietin receptor family MIY`"h0*  
',!>9Dj  
6. individual idiotype(IdI) _wUg+Xs]  
S5\KI+;PW  
7. integrin nh? JiH {  
Q%W>m0 %  
8. colony-stimulatory factor (CSF) w\a6ga!xt"  
ujf7r`;u.  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© wW7#M  
jB,VlL  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? 1[!7xA0j  
[Pl''[  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ 8x-(7[#e<g  
DDj:(I?,w  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠOVGB7CB]S  
[-Xah]g  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØϵ¡£ I~4!8W-Y  
\f7R^;`_<R  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) thz[h5C?C  
eQ*zi9na  
1. ÊÔÊö¸ÉÈÅËصķÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌص㡣Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËؼì²âµÄ·½·¨ºÍÔ­Àí¡£ bX 6uGu 7  
BS%pS(  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ä¿Ç°¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) |Mgzb0_IiQ  
lYmxd8  
3. immunoglobulin superfamily (IgSF) .)<l69ZD Z  
sQ+s3x1y  
4. selectin ,y@WFRsx  
q2s=>J';  
5. anti-idiotypic antibody (¦ÁId) !x! 1H5"  
5!aI~(3<  
6. major histocompatibility complex(MHC) +U4';[LG1C  
s> %.bAxc  
7. immunotolerance v]rbm}uU9  
P=7X+}@  
8. biological reponse modifier(BRM) egH,7f(yP  
WVz2 bzj  
9. immune reponse gene (Ir gene) y`z4S,  
/1_O5'5+v  
10. reshaped antibody (or reconstituted antibody) s p+'c;a  
^XG$?2<U  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Q g0%r bE  
JJ'f\f9  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ qJ2Z5  
Wf-XH|j[  
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? zF|c3ap  
s3  fQGbU  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ R / ND f`  
6:AEg  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? g<7Aln}Nl\  
?uU_N$x  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ r4<As`&  
4* I XBi7%  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? w'XN<RWA  
/t! 5||G  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ dp&G([  
U| ?68B3  
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺ 78 ]Kv^l^_  
4O.R=c2}7>  
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? IP@3R(DS%  
\)6bLB!  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ SlHDBr!.z  
/W .G- |:  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: .lM]>y)  
r=SC bv  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: q'4P/2)va  
(:O6sTx-hE  
ÃâÒßѧ |"S#uJW  
fM|s,'Q1x  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 6 VuyKt  
^fH)E"qq5  
1. CD8 4_sJ0=z-  
[\Nmm4  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) -84%6p2-  
iSR"$H{  
3. immunoglobulin fold(Ig fold) kPiY|EH  
N ~fE&@-  
4. cadherin (Ca-dependent cell adhesion moleculers) kFY2VPP~  
d*VvQU8C  
5. idiotype-anti-idiotypic antibody immune network theory aXG|IN5 *m  
I8% -ii  
6. HLA class II antigen eThFRU3 F  
%<+uJ'pj  
7. complementarity-determining region (CDR) NZ&ZK@h}.  
UN F\k1[  
8. perforin(or pore-forming protein ,PFP) 2+DK:T[  
EJMd[hMhe  
9. high affinity IL-2 receptor e`H>}O/ai  
%'_:#!9  
10. artificial active immunization DpeJ x  
l&qyLL2 w  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© _b>{:H&\  
>ov#\  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠi+in?!@G:  
qyFeq])  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 Eu~1t& 4  
wIR"!C>LE  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£  E>i<2  
vnVT0)Lel  
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԭ¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ rc<Ix  
tKcC{  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ 3**t'iWQ  
4e.19H9  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? |<,0 *2  
(n: A` ]  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ IHi[3xf<  
(~{Y}n]s  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ ,%N[FZ`|  
0A~UuH0.  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ !G[%; d  
!9YCuHj!p  
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ _->+Hjj ^  
<;W-!R759  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© Gos# =H  
cLwnV.  
1. immunoglobulin gene rearrangement <fDT/  
3)#Nc|  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) +[MHl  
P7,g^:$  
3. flow cytometry(FCM) ;L-)$Dy4  
s$fX ;  
4. carrier effect {D..(f1*u  
S2E z}*plp  
5. positive selection of T lymphocytes in thymus ]dJ"_  
X])iQyN  
6. mouse TH1(Th1) and TH2(Th2) subsets U?{oxy_[2  
.* 9u_2<  
7. perforin (pore-forming protein ,PFP) 0x5Ax=ut  
W!O/t^H>  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) ercXw7{  
ys`oHS f  
9. SH-2(src-homology region 2) o/V T"cT  
n YUFRV$  
10. Ab2¦Â (internal image) =M*pym]QSY  
R_+:nCB@,  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© % PB{jo  
1|xe'w{  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? L8h!%56s  
Cx/J_Ro#  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? EwV$2AK  
pKq[F*Lut  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ1?|"33\03R  
fw,,cu`YA  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ %} zkmEY.e  
pQ0*)}l,  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ{'M/wT)FeC  
GeY!f/yQ<  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) gM;m{gXYK  
FA{Q6fi:2  
ÃâÒßѧרҵ£º @SxZ>|r-|v  
XK/l1E3N  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ RDHK'PGA  
Q0jg(=9wP  
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? F5cN F 5  
:P2!& W  
´«È¾²¡Ñ§×¨Òµ£º W&9 qgbO]  
3]JJCaf  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ }1k?th  
L(Twclrb  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ O-UA2?N@j  
q\i&E Rr  
Ïû»¯×¨Òµ£º ~%h )G#N  
_)= e`9%  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ }UGSE2^1  
Pm2LB<qS  
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? Uq'W<.v 5  
u e  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ m5N,[^-  
=e#h;x2  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© U.~G{H`G,u  
s=jH1^  
1. Fas(CD95)/FasL 9"S iHp\)  
%$o[,13=  
2. common chain of cytokine receptor <aaT,J8%[  
w<!,mL5 N  
3 . TCR/CD3 complex ZEDvY=@a   
AHuIA{AdUR  
4. negaive selection of thymocytes #0h}{y E  
)XSHKPTQ1  
5. artificial active immune T'lycc4~a  
(m! kg  
6. anti-idiotypic .7Yox1,  
X8*~Cf73u  
7. IgSF 4*f+np  
5-fASN.Lx  
8. Integrin 9wf"5c  
v\G  7V  
9. chemokine k_u!E3{~  
Z 6Mjc/  
10. B7/CD28 w]h8KNt  
32aI0CT  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© [x, `)Fk  
& uwOyb  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ \X(*JNQ  
zXlerQWUv  
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 sb_/F E5e  
-\%5aXr  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ j$6Q]5KdoS  
WZ!zUUp}V  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ U8>4ClJ4  
vAop#V  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ v \; /P  
ct,;V/Dx  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ B9 ?58v&  
iYYuZ.  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© >tMI%r  
%}~(%@qB>+  
1. B7/CD28 g__s(  IJ  
eYkg4O'  
2. Th1 subset Us# /#-hJ  
87S,6Y  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© [%6)  
w03Ur4>T  
4. antibody affinity maturation \=|= (kt)  
rxy5Nrue  
5. AP-1 Ie _{P&J  
WL,2<[)Ew  
6. single chain variable fragment£¨ScFv£© D ZZRu8~  
Xnh&Kyz`v  
7. NK cell receptor <|G!Qn?2-  
j5/|1N  
8. Zinkernagel-Doherty phenomenon %2\Pe 2Z  
v,~f G>Y}  
9. Ig fold 1BEc"  
QKVOc,Fp7i  
10. CD40/CD40L @ %q>Jd  
4!96k~d}  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© ;+o6"ky5  
xA2I+r*o  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ cud9oJ-=;  
NZ!I >  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ B *6 ncj  
Kf$(7FT'`  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ AkO);4A;Jd  
uD{ xs  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ kv?DE4=;  
ug;\`.nT^  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ jr#*;go  
<_=O0 t| 6  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ O kT@ _U  
&U}8@;  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ w?N>3`Jnf  
@k'V`ZQF  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© <X& fs*x&  
:mf&,?  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© oj'YDQ^uj  
^si[L52BZ  
1.Co-stimulators (or co-stimulating molecules) EymSrZw  
>w.%KVBJ  
2.NK-kB Cp>y<C"  
S}]B|Q  
3.Immunoglobulin superfamily n^5Q f\o  
5gC> j(  
4.antigen-presenting cell (APC) Zp<#( OIu  
-Xw S?*O  
5.death domain `Gl[e4U  
E_Y!in 70  
6.CCR and CXCR MpJ<.|h  
:7dc;WdM  
7.Lectin (or mitogen) e5 zi"~  
bs16G3- p  
8.Clusters of differentiation, CD) hH%fWB2(  
hJir_=  
9.B7 family MLmaA3  
se=^K#o  
10.Cytotoxic T lymphocyte, CTL) \n^[!e"`  
u!F\`Gfm_  
11.IL-15 and IL-15 receptor (IL-15R) k"/Rjd(;  
I Xm[c@5l  
12.MHC restriction wrXn|aV  
3#>%_ @<  
13.Affinity-chromatography y c 8 h}`  
MEp{&#v|1  
14.Cyctosprin A, CsA 9$C?)XKXB  
DQ[7p(  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) ?.lo[X<,*  
qK9A /Mc  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© u%I%4 gM  
LXhR"PWZM\  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 "zCT S  
b0f6p>~q^  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ 8c_X`0jy  
u GqeT#dP  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 i1m>|[@k  
"bWx<  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 4gNN "  
2 >j0,2  
ÃâÒßѧרҵ£º s8P3H|0.-  
l(}L-:@A  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ / #rH18  
OJJ [Er1  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ v-q-CI? B#  
fiD,HGx i  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ ',t*:GBZCf  
{2D|,yH=  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) CYwV]lq :s  
Tcc83_Iq  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) J[hmY=,  
!J X7y%J  
1. ADCC(antibody dependent cell-mediated cytotoxicity) [[6" qq  
RjPkH$u'Pj  
2. »·æß¾úËØ(cyclosporin) ?CC.xE  
-o`K/f} d  
3. KIR(killer cell inhibitory receptor) Q@>1z*'I  
Qzo -Yw`=  
4. HLDA(human leucocyte differentiation antigen) xU0iz{9  
U1E@pDH  
5. Interleukin 18(IL-18) ~_ZK93o(  
?< teHFj  
6. ÕûºÏËØ(integrin) 3\ Mt+!1{  
D6&P9e_5  
7. Fas/FasL Dr V[1Z  
x$n.\`f0  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) ipp`99  
Us'JMZ~  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) 7vFmB  
HJ]e%og  
10. Th1/Th2 .S#i/A'x  
Sk!' 2y*@&  
11. »ùÒòÒßÃç(DNAÒßÃç) (@xC-*  
]GY8f3~|{  
12. chemokines and chemokine receptor xZ;eV76  
~K3Lbd| r  
13. ÃâÒßÄÍÊÜ eaDZ^Z Er  
|UWIV  
14. ¹²´Ì¼¤·Ö×Ó /*Q3=Dse]  
g_P98_2f.k  
15. ËÀÍö½á¹¹Óò(death domain) __QnzEF  
| |pOiR5  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) e.DN,rhqI  
&ZC{ _t  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? 6O6B8  
`Kf@<=  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ*qSvSY*  
}(Fmr7%m  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î zc;kNkV#1Y  
k# Ho7rS&  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ ),B/NZ/ -  
R--s u:  
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå 5~DKx7P!Z  
XfVdYmii  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ hN=kU9@knC  
gsM$VaF(  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) y< dBF[  
2INpo  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ JB'tc!!*  
_oBx:G6E  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ UF5_be,D  
NwYQ6VEA  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»